A Biobehavioral Model of Diabetes Risk in Chinese Immigrants



Status:Recruiting
Conditions:Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:35 - 65
Updated:12/3/2017
Start Date:January 2016
End Date:June 2021
Contact:Wanzi Yang, A.S.
Email:wanzi.yang@fccc.edu
Phone:215-728-4079

Use our guide to learn which trials are right for you!

This prospective, longitudinal study of Chinese American immigrants will examine whether
psychosocial factors (e.g., acculturative stress, social isolation, discrimination) are
associated with markers of type 2 diabetes risk over time, and whether such associations are
mediated by inflammatory pathways.

It is now well-documented that immigration to the US leads to increased risk for various
chronic diseases, including type 2 diabetes. The increased diabetes risk observed among
Chinese immigrants has been primarily attributed to changes in diet and weight gain following
immigration, but these changes can only partially explain disparities in disease risk. Models
of immigrant health suggest that the stress of adapting to life in a new country has a
considerable impact on physical health. However, few studies have considered the psychosocial
impact of immigration upon biomarkers of health and disease risk. Therefore, this
longitudinal study of US Chinese immigrant men and women will examine: (1) whether
psychosocial factors (e.g., acculturative stress, social isolation, discrimination) are
associated with markers of type 2 diabetes risk over time; and (2) whether the association
between psychosocial factors and diabetes risk markers is mediated by inflammatory pathways.

Inclusion Criteria:

- Chinese heritage;

- migration from Asia in adulthood (aged 18 years or older); and

- age 35-65 years

Exclusion Criteria:

- Current or prior history of diabetes

- Self-reported conditions of cancer, auto-immune disorders, HIV, or psychiatric illness

- Use of medications that may impact study outcomes (e.g., steroidal or non-steroidal
anti-inflammatory medications)

- Inability to provide informed consent.
We found this trial at
1
site
Philadelphia, Pennsylvania 19111
Principal Investigator: CAROLYN FANG
Phone: 215-728-4062
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials